On October 6, GRAIL, Inc. rose 6.76% in pre-market trading, trading at $156.93/share, with Turnover of $16.27万.

The movement extends the market's positive reaction to the FDA's Molecular and Clinical Genetics Devices Advisory Committee vote on Galleri. The committee voted 10-0 in favor of safety, 6-4 on efficacy, and 7-2 with one abstention on benefit-risk profile. PATHFINDER 2 trial data showed adding Galleri to standard screening increased cancer detection 6.5-fold, with 71% of newly identified cancers detected at stages I to III. While the advisory committee's recommendation is non-binding, UBS recently raised its target price to $175, maintaining a Buy rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)